|Dr. Alexander D. Macrae M.B., Ch.B, Ph.D., MRCP||Pres, CEO & Director||697k||N/A||54|
|Mr. Curt A. Herberts III||Sr. VP & Chief Bus. Officer||362.26k||N/A||36|
|Dr. Edward R. Conner M.D.||Sr. VP & Chief Medical Officer||134.85k||N/A||44|
|Ms. Kathy Y. Yi||Sr. VP & CFO||N/A||N/A||45|
|Dr. R. Andrew Ramelmeier||Sr. VP and Head of Technical Operations & Manufacturing||N/A||N/A||N/A|
Sangamo Therapeutics, Inc. focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off. Its therapeutic products include SB-728-T, a ZFN-mediated autologous T-cell product for human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS), which is in Phase II and Phase I clinical trials; and SB-728-HSPC that is in Phase I/II clinical trials for HIV/AIDS. The company also engages in Phase I/II studies of in vivo genome editing applications of ZFP Therapeutics for hemophilia B, Hemophilia A, and Mucopolysaccharidosis I (MPS) and MPS II, which are lysosomal storage disorder (LSD); preclinical programs in other LSDs; and research stage programs in central nervous system disorders and cancer immunotherapies. It has collaborative partnerships with Biogen Inc. to develop therapeutic genome editing products in hemoglobinopathies; and Shire International GmbH to develop the preclinical development program in Huntington's disease, as well as license agreements with Sigma-Aldrich Corporation to develop ZFP-based laboratory research reagents and Dow AgroSciences, LLC to modify the genomes or alter protein expression of plant cells and plants. The company also has a research collaboration and license agreement with Pfizer Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Richmond, California.
Sangamo Therapeutics, Inc.’s ISS Governance QualityScore as of February 1, 2018 is 4. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 2; Compensation: 6.